303 related articles for article (PubMed ID: 18596031)
1. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
2. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
3. NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase.
Hisatomi T; Sueoka-Aragane N; Sato A; Tomimasu R; Ide M; Kurimasa A; Okamoto K; Kimura S; Sueoka E
Blood; 2011 Mar; 117(13):3575-84. PubMed ID: 21245486
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Guo L; Liu X; Nishikawa K; Plunkett W
Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
[TBL] [Abstract][Full Text] [Related]
5. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
[TBL] [Abstract][Full Text] [Related]
6. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Ma Y; North BJ; Shu J
Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
8. DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor.
Guo L; Liu X; Jiang Y; Nishikawa K; Plunkett W
Mol Pharmacol; 2011 Aug; 80(2):321-7. PubMed ID: 21546556
[TBL] [Abstract][Full Text] [Related]
9. Replication-dependent and transcription-dependent mechanisms of DNA double-strand break induction by the topoisomerase 2-targeting drug etoposide.
Tammaro M; Barr P; Ricci B; Yan H
PLoS One; 2013; 8(11):e79202. PubMed ID: 24244448
[TBL] [Abstract][Full Text] [Related]
10. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
11. The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target.
Alchanati I; Teicher C; Cohen G; Shemesh V; Barr HM; Nakache P; Ben-Avraham D; Idelevich A; Angel I; Livnah N; Tuvia S; Reiss Y; Taglicht D; Erez O
PLoS One; 2009 Dec; 4(12):e8104. PubMed ID: 19956605
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T
Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565
[TBL] [Abstract][Full Text] [Related]
13. Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle.
Li M; Miao ZH; Chen Z; Chen Q; Gui M; Lin LP; Sun P; Yi YH; Ding J
Ann Oncol; 2010 Mar; 21(3):597-607. PubMed ID: 19773249
[TBL] [Abstract][Full Text] [Related]
14. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
[TBL] [Abstract][Full Text] [Related]
15. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
[TBL] [Abstract][Full Text] [Related]
16. Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes.
Hoa NN; Shimizu T; Zhou ZW; Wang ZQ; Deshpande RA; Paull TT; Akter S; Tsuda M; Furuta R; Tsutsui K; Takeda S; Sasanuma H
Mol Cell; 2016 Nov; 64(3):580-592. PubMed ID: 27814490
[TBL] [Abstract][Full Text] [Related]
17. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.
Azarova AM; Lyu YL; Lin CP; Tsai YC; Lau JY; Wang JC; Liu LF
Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11014-9. PubMed ID: 17578914
[TBL] [Abstract][Full Text] [Related]
18. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.
Lee CH; Hsieh MY; Hsin LW; Chen HC; Lo SC; Fan JR; Chen WR; Chen HW; Chan NL; Li TK
Biochem Pharmacol; 2012 May; 83(9):1208-16. PubMed ID: 22306066
[TBL] [Abstract][Full Text] [Related]
19. The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.
Bombarde O; Larminat F; Gomez D; Frit P; Racca C; Gomes B; Guilbaud N; Calsou P
Mol Cancer Ther; 2017 Oct; 16(10):2166-2177. PubMed ID: 28611105
[TBL] [Abstract][Full Text] [Related]
20. The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase II
Kanagasabai R; Karmahapatra S; Kientz CA; Yu Y; Hernandez VA; Kania EE; Yalowich JC; Elton TS
Mol Pharmacol; 2018 May; 93(5):515-525. PubMed ID: 29514855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]